Wondering how a medicine gets from a lab bench to a pharmacy shelf? The FDA approval process runs in five steps: discovery, preclinical research, clinical research, agency review and post-market monitoring.
| Item | Value |
|---|---|
| Steps in the FDA drug development process | 5 steps, from discovery to post-market safety monitoring |
| FDA review of an original IND submission | 30 days |
| Decision time for a complete NDA | 6 to 10 months |
| Data an NDA must include | Everything from preclinical data to Phase 3 trial data |
| Safety monitoring after approval | Continues while the product is on the market |
Figures come from a university training page that summarises the FDA’s process: Biotility drug development overview. Timelines and rules can change, so check the source before you rely on them.
What the FDA approval process actually is
The FDA is the United States agency that decides whether a new drug may be sold. Developers do not simply submit a finished product and wait. They move through stages, and each one produces evidence that the next stage builds on.
The same training page notes that the complexity of drug development has greatly increased over the past 40 years. That is why so many roles exist around it, from lab scientists to regulatory writers. If you want the wider industry picture, the biotech industry hub explains where these jobs sit.
This guide covers drugs. Devices follow related but different routes, which are not detailed here.
Think of the process as a series of gates. At each gate, someone asks whether the evidence so far justifies spending more time, money and patient effort on the next stage.
That design protects the people who volunteer for trials and the patients who eventually take the medicine. It also explains why development is slow and why most candidates never reach a pharmacy.
The five steps from idea to pharmacy
The Biotility page lays out the path as five numbered steps:
- Discovery and development: research for a new drug begins in the laboratory.
- Preclinical research: laboratory and animal testing answers basic questions about safety.
- Clinical research: the drug is tested on people to check that it is safe and effective.
- FDA review: review teams examine all the submitted data and decide whether to approve.
- Post-market safety monitoring: the FDA keeps watching safety once the product is in public use.
Notice that approval is step four, not the finish line. Safety work carries on afterwards.
The steps are not owned by a single employer. A university lab may handle the first, a small company the next few, and a large company the later ones. Each hand-off needs careful documentation so the next team can trust the data.
Good documentation is a quiet theme across the whole path. Regulators can only judge what has been recorded, so clear records are part of nearly every job in the chain.
Before people: discovery and preclinical work
Discovery starts with many tests of molecular compounds, looking for possible beneficial effects against disease. Most compounds go nowhere. A few look promising enough to move forward.
Preclinical research then asks a blunt question. Before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. These studies must also give detailed information on dosing and toxicity levels.
After preclinical testing, researchers review their findings and decide whether the drug should be tested in people. Many careers sit here: toxicologists, pharmacologists, lab technicians and study managers.
Getting permission to test in people: the IND
Before human studies begin, the developer files an Investigational New Drug (IND) application. It describes the planned study and the preclinical results behind it. Developers design the clinical study with each phase of clinical research in mind, and they begin the IND process before that research starts.
The FDA review team has 30 days to review the original IND submission. Trials can begin after the 30-day waiting period if FDA has imposed no clinical hold and the required institutional review board approval is in place. For a closer look at how those trials are run and staffed, read about what is clinical research.
The marketing application and the FDA’s decision
When the evidence is ready, the developer files a New Drug Application (NDA). It must include everything about the drug, from preclinical data to Phase 3 trial data. This is a very large package, and assembling it is a major job for regulatory affairs teams.
Once the FDA receives it, the review team first checks whether it is complete. If it is not complete, the review team can refuse to file the NDA.
If it is complete, the review team has 6 to 10 months to decide whether to approve the drug. The shorter end of that range is not a promise for every drug, so treat it as a typical window rather than a guarantee.
After approval: safety keeps being checked
Approval does not end the FDA’s interest. The agency monitors the safety of drugs and devices once they are available to the public.
There is a good reason. A product’s true safety picture evolves over the months and even years of its time on the market, because far more people use it than ever joined a trial.
That is why pharmacovigilance and drug safety roles exist inside companies. They collect and assess reports of problems after launch.
Trials are designed to answer specific questions in a controlled group. Real-world use is wider and messier, so rarer effects can surface only once many people are taking the drug. Monitoring is how those signals are caught and acted on.
What this means if you are weighing a biotech career
Different employers cover different stretches of this path. Some small firms stop at early research, while large ones run the whole route. The guide to types of biotech companies shows how that split looks in practice.
Knowing the five steps helps you read job adverts and judge what a role really involves. A posting that mentions submissions and agency correspondence points to the review stage, while one about animal studies points to preclinical work.
It also helps in interviews. You can explain where a role fits in the chain, which shows you understand why the work is done carefully.
Keep in mind that this page summarises a single training resource, so treat it as an orientation rather than a regulatory reference.
These roles relate to different parts of the process, and some span multiple stages.
Frequently asked questions
How long does the FDA take to review a new drug?
Show answer
According to the Biotility overview, once an NDA is judged complete the review team has 6 to 10 months to decide. That excludes the earlier research and trial years.
What is the difference between an IND and an NDA?
Show answer
An IND is filed before human testing begins, and the FDA team has 30 days to review the original submission. An NDA is filed after the trials and asks for permission to market the drug.
Can the FDA refuse to look at an application?
Show answer
Yes. An incomplete NDA can be refused filing before full substantive review begins.
Does the FDA stop watching a drug once it is approved?
Show answer
No. The agency monitors safety once products are available to the public, because the full safety picture develops over months and years of use.
